Connect with us

Technology

Digital Pathology Market size is set to grow by USD 1.12 billion from 2024-2028, Growing adoption of IoT infrastructure among laboratories boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global digital pathology market size is estimated to grow by USD 1.12 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 16.98% during the forecast period. Growing adoption of iot infrastructure among laboratories is driving market growth, with a trend towards integration of ai into digital pathology systems. However, issues regarding privacy and safety of a digital database poses a challenge.Key market players include 3DHISTECH Ltd., Apollo Enterprise Imaging Corp., Co Diagnostics Inc., Corista, Danaher Corp., F. Hoffmann La Roche Ltd., General Electric Co., Hamamatsu Photonics KK, Huron Digital Pathology, Indica Labs Inc., Inspirata Inc., Kanteron Systems SLU, Koninklijke Philips N.V., Mikroscan Technologies Inc., Objective Pathology Services, Olympus Corp., Proscia Inc., Sectra AB, Visiopharm AS, and XIFIN Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Digital Pathology Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 16.98%

Market growth 2024-2028

USD 1124.2 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

14.12

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key countries

US, UK, Germany, France, and Canada

Key companies profiled

3DHISTECH Ltd., Apollo Enterprise Imaging Corp., Co Diagnostics Inc., Corista, Danaher Corp., F. Hoffmann La Roche Ltd., General Electric Co., Hamamatsu Photonics KK, Huron Digital Pathology, Indica Labs Inc., Inspirata Inc., Kanteron Systems SLU, Koninklijke Philips N.V., Mikroscan Technologies Inc., Objective Pathology Services, Olympus Corp., Proscia Inc., Sectra AB, Visiopharm AS, and XIFIN Inc.

Market Driver

The integration of artificial intelligence (AI) in digital pathology is revolutionizing clinical workflows, particularly in image analysis and machine-learning algorithms. Whole slide scanning technology, combined with AI, offers efficient image recognition and automated diagnostic capabilities. Market vendors are developing AI-powered software for digital pathology, focusing on automation in image analytics, decision-making, and result interpretations. These intelligent applications address the shortage of trained pathology professionals, fueling demand for AI-integrated digital pathology systems. Notable vendors, like Indica Labs and Visiopharm AS, have already launched AI-based platforms, HALO AI and Oncotopix, respectively. Meanwhile, other companies, including Huron Technologies International, Danaher, and Koninklijke Philips, are continuously enhancing their AI platforms and applications through strategic initiatives, which is anticipated to boost sales and increase the commercial availability of these systems during the forecast period.

The Digital Pathology market is experiencing significant growth due to the adoption of advanced technologies like Pathology Software, Pathology Imaging Systems, and Whole Slide Imaging. Pathology vendors are developing innovative solutions, including Pathology Training platforms and AI Integration for improved accuracy and efficiency. Pathology Data Security and Sharing are crucial concerns, with vendors focusing on robust systems for safeguarding patient information. Telepathology and Virtual Microscopy enable remote consultations and second opinions, enhancing patient care. Pathology Informatics and Analytics provide valuable insights, while Decision Support systems aid in faster and more accurate diagnoses. Digital Pathology Workstations and Workflow solutions streamline processes, and Collaboration tools facilitate seamless communication among healthcare professionals. Digital Pathology Services offer comprehensive solutions, including Reporting and Integration with Electronic Health Records. AI Pathology algorithms are revolutionizing diagnosis, offering precision and consistency. Overall, the Digital Pathology market is transforming Pathology Technology, offering numerous benefits to patients and healthcare providers alike.

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

Digital pathology systems have streamlined laboratory processes by enabling digital acquisition, storage, manipulation, viewing, sharing, and transmission of glass slide images. However, the security and safety of these digital pathology data have become a significant concern for hospitals, reference laboratories, research institutes, and other end-users. The primary apprehensions revolve around the use of dependable data storage architectures. With the declining cost of cloud-based storage, digital pathology system providers advocate for cloud-based storage solutions due to their customized storage capabilities, capable of handling large data sizes, ranging from 1.2GB to 2GB per slide. However, cloud-based services are susceptible to external breaches, which could result in data loss and security breaches, potentially damaging the reputation and trust of end-user organizations. The increasing number of pathology data breaches worldwide has intensified the need for data safety services and heightened spending on securing sensitive databases. These concerns may hinder the growth of the digital pathology market during the forecast period.The Digital Pathology market is experiencing significant growth due to the adoption of advanced technologies like Whole Slide Imaging, Telepathology, and AI Pathology. Pathology software vendors are meeting the demand for digital solutions, providing tools for image storage, retrieval, and sharing. Pathology training and education are essential for effective implementation, with a focus on data security and patient care. Pathology imaging systems and scanners are key components, offering high-quality images for accurate diagnosis. Pathology workstations and decision support systems aid in efficient diagnosis and reporting. AI integration and analytics enhance diagnostic capabilities, enabling faster and more accurate results. Pathology informatics and digital pathology solutions streamline workflow and collaboration, enabling remote second opinions and integration with electronic health records. Data security remains a top concern, with solutions ensuring secure storage and sharing of sensitive patient information. The market trends include virtual microscopy, digital archiving, and telepathology services, offering convenience and cost savings. Overall, digital pathology technology is revolutionizing the field, improving patient care and diagnostic accuracy.

For more insights on driver and challenges – Request a sample report!

Segment Overview

This digital pathology market report extensively covers market segmentation by

Product1.1 Digital slide scanner1.2 SoftwareApplication2.1 Hospitals and laboratories2.2 Independent and small clinics2.3 Research centersGeography3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Digital slide scanner- The digital slide scanner segment holds the largest share in the global digital pathology market due to the increasing adoption in academic institutions for research activities and the enhanced resolution of slide images. Technological advancements in slide magnification and scanning further fuel the segment’s growth. Notable developments, such as Hamamatsu Photonics’ launch of the NanoZoomer S20MD Slide scanner system, which scans a slide every 30 seconds, enable pathologists to focus more on analysis. Rising internet bandwidth connectivity and continuous technological improvements from market vendors contribute to the market’s expansion.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

Digital Pathology is a subspecialty of pathology that utilizes digital images of glass slides for diagnosis and analysis. Pathology Software is essential for managing and interpreting these images, enabling features such as Whole Slide Imaging, Telepathology, and AI Pathology. Virtual Microscopy and Remote Pathology allow pathologists to access and review slides from anywhere, while Pathology Informatics and Pathology Workflow solutions streamline the diagnostic process. Pathology Reporting and Integration ensure seamless communication between healthcare providers, and Pathology Cloud Storage provides secure, accessible storage for digital slides. Pathology Market Trends include increasing adoption of digital pathology, advancements in AI algorithms, and the integration of teleconsultation and quality assurance measures. Pathology Imaging Systems, Pathology Scanners, and Pathology Laboratories are key components of digital pathology workflows, while Pathology Management solutions help optimize operations and improve efficiency. Pathology AI Algorithms and Pathology Software Vendors continue to innovate and drive the digital pathology market forward.

Market Research Overview

Digital Pathology is a rapidly evolving field that leverages technology to enhance traditional pathology practices. It includes Pathology Software solutions, such as Whole Slide Imaging (WSI) and Virtual Microscopy, which enable the digitization and remote viewing of glass slides. Telepathology and AI Pathology are key components, offering real-time consultations and advanced diagnostic capabilities through AI algorithms. Pathology Analytics provides valuable insights from large data sets, while Pathology Informatics manages and integrates data across the entire pathology workflow. Digital Pathology Solutions streamline processes, from Pathology Workflow and Collaboration to Reporting and Integration. Pathology Services include Digital Archiving, Image Storage, Retrieval, and Decision Support. Pathology Workstations and AI Integration facilitate efficient diagnosis and patient care. Pathology Technology continues to advance, with trends towards increased automation, data sharing, and security. Pathology Scanners and Imaging Systems provide high-quality images for analysis, while Training and Education ensure professionals remain up-to-date with the latest techniques and tools.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductDigital Slide ScannerSoftwareApplicationHospitals And LaboratoriesIndependent And Small ClinicsResearch CentersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/digital-pathology-market-size-is-set-to-grow-by-usd-1-12-billion-from-2024-2028–growing-adoption-of-iot-infrastructure-among-laboratories-boost-the-market-technavio-302209857.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets

Published

on

By

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform

TOKYO, April 14, 2025 /PRNewswire/ — PRISM BioLab, Co. Ltd. (“PRISM BioLab”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc. (“Elix”), effective April 1, 2025.

This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab’s proprietary peptide mimetic technology for controlling protein-protein interactions with Elix’s cutting-edge AI drug discovery platform.

In drug discovery, generating a clinical candidate molecule typically takes long time and requires synthesis of hundreds to thousands of compounds, making research and development efficiency a critical challenge. Through this partnership, PRISM BioLab’s proprietary small molecule peptide-mimetic PepMetics® technology will be integrated with Elix’s AI drug discovery platform “Elix Discovery™.” This collaboration will expand the AI search range to include previously unconsidered small molecules, enabling efficient identification of promising compounds for traditionally difficult targets and accelerating the creation of breakthrough drug candidates. By leveraging both companies’ AI capabilities and medicinal chemistry expertise, the partnership aims to reduce time and costs and improve success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs.

Comments from Executives

Elix co-founder and CEO Shinya Yuki, Ph.D.:

In our previous pilot project with PRISM BioLab, we achieved breakthrough results by creating novel compound candidates with an efficiency that would be unimaginable using conventional approaches. This success clearly demonstrated that the combination of our companies’ technologies and expertise holds tremendous potential in drug discovery. I am genuinely looking forward to this business partnership, where we can leverage our complementary strengths to pursue outcomes that neither company could achieve alone.

PRISM BioLab CEO Dai Takehara:

As we challenge ourselves to ‘create new areas of drug discovery’ with peptide-mimetic small molecules, AI utilization is essential. We expect our efforts to be significantly accelerated through collaboration with Elix, whose mission is to ‘rethink drug discovery.’ Our pilot project has already demonstrated the synergistic effect of our technologies and team collaboration, and we will continue to pursue the early creation of groundbreaking new drugs together.

PRISM BioLab CTO Tatsuya Toma Ph.D.:

Improving drug discovery efficiency is an eternal challenge. Delivering better medicines to patients and healthcare professionals as quickly as possible requires innovation. Our PepMetics® technology has characteristics that are highly compatible with AI applications. Elix is not only a professional in AI and machine learning but also expanding their knowledge and understanding of drug discovery while maintaining a flexible corporate culture. They have shown great interest in PepMetics® features, and I believe we can advance comprehensive drug discovery research together, leveraging PepMetics® characteristics to accelerate the process.

About Elix

Elix is an AI drug discovery company with the mission of “Rethinking drug discovery”. Through their flagship software platform, Elix Discovery™, and collaborative consulting engagements, they work with leading pharmaceutical companies and biotech startups to reduce the enormous costs and time associated with drug discovery, while improving the rate of successful outcomes. They achieve these goals via their company’s unique blend of AI engineering and medicinal chemistry expertise that allows them to stay at the forefront of development in both fields, and offer the solutions of tomorrow to the problems of today.

https://www.elix-inc.com/ 

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceutical Co., Ltd. are in clinical development for cancer and liver disease, respectively.

www.prismbiolab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/prism-biolab-and-elix-join-forces-to-accelerate-ai-driven-drug-discovery-for-protein-protein-interaction-targets-302426497.html

SOURCE PRISM BioLab Co., Ltd.

Continue Reading

Technology

RIAD Corp. reveals AI-powered hotel group booking platform Ria at ITB Berlin 2025

Published

on

By

BERLIN, April 14, 2025 /PRNewswire/ — Riad Corporation, a leading AI-powered travel technology company, successfully launched its flagship product, RIA 1.0, at ITB Berlin 2025, one of the world’s largest travel trade shows. The company attracted over 300 visitors to its booth and secured 150 enterprise client sign-ups during the three-day event, marking a major milestone for its global expansion.

RIA 1.0 is an advanced AI platform that fully automates group hotel reservations, tailored for travel agencies and corporate clients handling complex requirements. Unlike traditional systems, RIA enables both direct bookings and customized group requests, processed entirely by AI without manual work. The platform simplifies large-scale, multi-hotel bookings — tasks that usually take days — completing them in minutes.

During ITB Berlin, Riad Corporation presented live demonstrations showing how RIA’s AI engine handles diverse, high-volume booking scenarios. Attendees praised its intuitive interface, seamless integration, and real-time responses to specific client needs, including corporate events, MICE bookings, and incentive groups.

Mike Lee, CEO of Riad Corporation, commented, “Meeting so many global partners at ITB Berlin was truly meaningful, and we are proud to showcase our technology to the world,” adding, “We will continue to focus on R&D to deliver stronger innovations and achieve greater success globally.”

In addition, Riad Corporation announced plans to launch AI-based group flight booking services later this year, transforming RIA into a comprehensive group travel platform covering both hotels and flights.

RIA has already gained momentum in Southeast Asia, with over 800 enterprise clients, and aims to reach 2,000 clients by the end of 2025.

Riad Corporation’s strong debut at ITB Berlin reflects rising demand for AI-driven solutions in travel. As group travel grows more complex, RIA 1.0 is positioned to lead the market with unmatched speed, accuracy, and automation.

For more information about Riad’s solution RIA, visit ‘www.ria-travel.com‘.

Photo – https://mma.prnewswire.com/media/2646943/ria.jpg
Logo – https://mma.prnewswire.com/media/2646944/RIAD_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/riad-corp-reveals-ai-powered-hotel-group-booking-platform-ria-at-itb-berlin-2025-302424402.html

Continue Reading

Technology

GameChange Solar Closes FY 25 in India with Strong Order Momentum

Published

on

By

Order bookings exceed 7 GW in FY25Total India projects (commissioned as well as under installation) cross 13 GWOver 20 GW local manufacturing capacity for key components

BENGALURU, India , April 14, 2025 /PRNewswire/ — GameChange Solar, a leading global supplier of solar tracker and fixed-tilt racking technology, has closed FY 25 on a strong note in the Indian market, with total order bookings of 7 GW. Of this, nearly 2 GW of tracker orders were signed in Q4 FY 25, marking a robust end to the financial year.

With this milestone, GameChange Solar’s total projects in India (commissioned as well as under installation) have now exceeded 13 GW, reinforcing its position as a trusted technology partner in the country’s growing utility-scale solar segment. A significant portion of these new orders represents repeat business from clients, reflecting GameChange Solar’s proven performance, consistent execution, and customer-first approach.

To support this growth, the company’s local manufacturing capacity for key components has surpassed 20 GW annually, enabling faster deliveries and stronger alignment with project timelines.

India continues to be one of the most exciting and dynamic solar markets globally, and this strong finish to FY 25 reflects the valued relationships we’ve built with our customers and the reliability of our Genius Tracker™ systems,” said Vikas Bansal, President – International at GameChange Solar. “What’s particularly encouraging is the consistency of demand across states, developer profiles, and project sizes – from first-time engagements to repeat orders. It shows that the market isn’t just growing, it’s maturing, and there’s a clear preference for scalable, execution-focused partners who can deliver at speed.”

GameChange Solar’s Genius Tracker™ solutions are engineered for high-wind, high-heat environments – combining speed, structural durability, and precision tracking to maximize output and reduce project timelines. Their versatility makes them ideally suited for India’s diverse terrains and aggressive commissioning schedules.

For more information about GameChange Solar and its solar tracking solutions, visit www.gamechangesolar.com

About GameChange Solar

GameChange is the second largest global provider of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 43 GW of solar tracker and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun’s movement across the sky and optimize plant performance while protecting the array from damaging weather conditions.

Media Contact

Nisha Wadhwani

Lead – Marketing, GameChange Solar

nisha.wadhwani@gamechangesolar.com

Logo – https://mma.prnewswire.com/media/1592922/GameChange_Solar_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/gamechange-solar-closes-fy-25-in-india-with-strong-order-momentum-302426929.html

Continue Reading

Trending